What should patients avoid when taking Fenofibrate?

Patients taking Fenofibrate should avoid using it if they have severe kidney or liver disease because the drug is metabolized in the liver and excreted by the kidneys. In individuals with compromised liver function, Fenofibrate can accumulate in the body, increasing the risk for toxicity and adverse effects. Similarly, in patients with severe kidney disease, the risk of accumulation also heightens, potentially leading to serious complications such as muscle pain or damage (rhabdomyolysis).

This caution is vital for patient safety, as both liver and renal impairment can significantly alter the pharmacokinetics of many medications, including Fenofibrate, making careful screening of kidney and liver function essential before initiating therapy with the drug. Monitoring and adjusting doses may be necessary in patients with milder forms of impairment, but severe conditions warrant avoiding the drug entirely.